Drug Trial Radar · NCT06155084
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Dec 26, 2023
Primary completion
Mar 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
HP518 - Dose EscalationDrug
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
HP518 - Dose EscalationDrug
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
HP518 -Dose ExpansionDrug
Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1)Time frame: 28 DAYS
- Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousnessTime frame: Through study completion, an average of 1 year
- Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
- Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
- Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
- PSA50 response rateTime frame: 12 weeks
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital Of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
The Second Affiliated Hospital Of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital Of Xiamen Univeristy
Xiamen, Fujian, China · Not yet recruiting
Lanzhou University Second Hospital
Lanzhou, Gansu, China · Recruiting
The Third Affiliated Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
The Affiliated Hospital Of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Zhengzhou Central Hospital
Zhengzhou, Henan, China · Recruiting
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Recruiting
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China · Recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital Of Xi'An Jiaotong Univeristy
Xi’an, Shanxi, China · Recruiting
Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
West China Hospital Of Sichuan University
Chengdu, Sichuan, China · Recruiting
The Affiliated Hospital Of Southwest Medical University
Luzhou, Sichuan, China · Recruiting
Mianyang Central Hospital
Mianyang, Sichuan, China · Recruiting
The Second Affiliated Hospital Of Kunming Medical University
Kunming, Yunnan, China · Recruiting
The Affiliated Hospital Of School Of Medicine Of Ningbo University
Ningbo, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.